Literature DB >> 15224183

Proteins interacting with the 26S proteasome.

R Hartmann-Petersen1, C Gordon.   

Abstract

The 26S proteasome is the multi-protein protease that recognizes and degrades ubiquitinylated substrates targeted for destruction by the ubiquitin pathway. In addition to the well-documented subunit organization of the 26S holoenzyme, it is clear that a number of other proteins transiently associate with the 26S complex. These transiently associated proteins confer a number of different roles such as substrate presentation, cleavage of the multi-ubiquitin chain from the protein substrate and turnover of misfolded proteins. Such activities are essential for the 26S proteasome to efficiently fulfill its intracellular function in protein degradation.

Mesh:

Substances:

Year:  2004        PMID: 15224183     DOI: 10.1007/s00018-004-4132-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  61 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

Review 2.  Anticoagulant therapy for percutaneous coronary intervention.

Authors:  Sunil V Rao; E Magnus Ohman
Journal:  Circ Cardiovasc Interv       Date:  2010-02-01       Impact factor: 6.546

3.  Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

Authors:  Gilles Montalescot; Leonardo Bolognese; Dariusz Dudek; Patrick Goldstein; Christian Hamm; Jean-Francois Tanguay; Jurrien M ten Berg; Debra L Miller; Timothy M Costigan; Jochen Goedicke; Johanne Silvain; Paolo Angioli; Jacek Legutko; Margit Niethammer; Zuzana Motovska; Joseph A Jakubowski; Guillaume Cayla; Luigi Oltrona Visconti; Eric Vicaut; Petr Widimsky
Journal:  N Engl J Med       Date:  2013-09-01       Impact factor: 91.245

4.  Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).

Authors:  Gilles Montalescot; Stephen G Ellis; Mark A de Belder; Luc Janssens; Olivier Katz; Wladyslaw Pluta; Patrick Ecollan; Michal Tendera; Ad J van Boven; Petr Widimsky; Henning R Andersen; Amadeo Betriu; Paul Armstrong; Bruce R Brodie; Howard C Herrmann; Franz-Josef Neumann; Mark B Effron; Jiandong Lu; Elliot S Barnathan; Eric J Topol
Journal:  JACC Cardiovasc Interv       Date:  2010-02       Impact factor: 11.195

5.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

6.  2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Alice K Jacobs
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

7.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.

Authors:  J W Eikelboom; S S Anand; K Malmberg; J I Weitz; J S Ginsberg; S Yusuf
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

8.  Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

Authors:  Harvey D White; Neal S Kleiman; Kenneth W Mahaffey; Yuliya Lokhnygina; Karen S Pieper; Karen Chiswell; Marc Cohen; Robert A Harrington; Derek P Chew; John L Petersen; Lisa G Berdan; Philip E G Aylward; Christopher C Nessel; James J Ferguson; Robert M Califf
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

9.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

Authors:  Rikke Sørensen; Morten L Hansen; Steen Z Abildstrom; Anders Hvelplund; Charlotte Andersson; Casper Jørgensen; Jan K Madsen; Peter R Hansen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

10.  Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.

Authors:  Morten Lamberts; Jonas Bjerring Olesen; Martin Huth Ruwald; Carolina Malta Hansen; Deniz Karasoy; Søren Lund Kristensen; Lars Køber; Christian Torp-Pedersen; Gunnar Hilmar Gislason; Morten Lock Hansen
Journal:  Circulation       Date:  2012-08-06       Impact factor: 29.690

View more
  17 in total

1.  Implications for proteasome nuclear localization revealed by the structure of the nuclear proteasome tether protein Cut8.

Authors:  Kojiro Takeda; Nam K Tonthat; Tiffany Glover; Weijun Xu; Eugene V Koonin; Mitsuhiro Yanagida; Maria A Schumacher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-05       Impact factor: 11.205

2.  Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and degradation of tumor necrosis factor receptor II.

Authors:  Alicia S Chung; Ying-Jie Guan; Zheng-Long Yuan; Jorge E Albina; Y Eugene Chin
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

Review 3.  Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin.

Authors:  E Malito; R E Hulse; W-J Tang
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

Review 4.  Oxidative stress-mediated regulation of proteasome complexes.

Authors:  Charity T Aiken; Robyn M Kaake; Xiaorong Wang; Lan Huang
Journal:  Mol Cell Proteomics       Date:  2011-05       Impact factor: 5.911

5.  The Rad23 ubiquitin receptor, the proteasome and functional specificity in transcriptional control.

Authors:  Staton L Wade; David T Auble
Journal:  Transcription       Date:  2010 Jul-Aug

6.  hRpn13, a newly identified component of the 19S particle, regulates proliferation, differentiation, and function in the human osteoblast-like cell line MG63. [corrected].

Authors:  Xi Zhao; Yonglie Chao; Pixiu Chen; Die Liu; Peng Su; Jian Sun; Xuqin Cui; Yaxiong Tang
Journal:  J Physiol Biochem       Date:  2011-11-05       Impact factor: 4.158

Review 7.  Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.

Authors:  James J Driscoll; Roopa Dechowdhury
Journal:  Target Oncol       Date:  2010-11-27       Impact factor: 4.493

8.  Characterization of cell cycle specific protein interaction networks of the yeast 26S proteasome complex by the QTAX strategy.

Authors:  Robyn M Kaake; Tijana Milenković; Natasa Przulj; Peter Kaiser; Lan Huang
Journal:  J Proteome Res       Date:  2010-04-05       Impact factor: 4.466

Review 9.  Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Mediators Inflamm       Date:  2010-04-12       Impact factor: 4.711

10.  Together, Rpn10 and Dsk2 can serve as a polyubiquitin chain-length sensor.

Authors:  Daoning Zhang; Tony Chen; Inbal Ziv; Rina Rosenzweig; Yulia Matiuhin; Vered Bronner; Michael H Glickman; David Fushman
Journal:  Mol Cell       Date:  2009-12-25       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.